Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized, partially double-blind study of PR5I in infants
2011-004108-39Phase 3
- Sponsor
- Sanofi
- Start
- Feb 2012
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by Sanofi. Primary endpoints: Primary immunogenicity endpoints and Primary immunogenicity lot-consistency response rates.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2011-004108-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004108-39.